Weight-loss jab Wegovy sees another prescription boost after ban on copycats - Novo CEO ousted in May, in place until ...

Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid ...

GoodRx reports that insurance coverage for GLP-1 medications varies. It's more likely when prescribed for FDA-approved uses ...

Powerful new medications such as Ozempic and Mounjaro, known as GLP-1 drugs are helping to win the war against obesity in ...

US lawmakers are pushing the Food and Drug Administration to control the increasing market of fake weight-loss medications.

Experts say there’s no evidence GLP-1s can be absorbed through the skin — and these patches don’t contain the FDA-approved ...

More than 80 U.S. lawmakers asked the FDA to stop counterfeit GLP-1 drugs linked to Chinese suppliers from entering the ...

A recipient of the 2025 Elite Trial Lawyers Lifetime Achievement Award, Morgan & Morgan's John Yanchunis spoke with the National Law Journal about his storied career, from bringing one of the nation’s ...

Several anti-obesity drugs, including Ozempic, Wegovy and Mounjaro, have created buzz in the Indian markets. But are they really approved for use in India? What are their side-effects? And how much do ...

Companies are selling personalized compounded drugs that combine weight loss and erectile dysfunction treatments, but is this ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by CVS Caremark.

China's Sciwind Biosciences is in talks with a U.S. company interested in licensing its experimental weight-loss drug for ...